Hany Salama

Mr. Hany Salama

Vice President, Worldwide Operations, NEOSTRATA COMPANY, INC.


          What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

GLG News by Mr. Hany Salama, Vice President, Worldwide Operations

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

CROs - Beyond Cost Savings

May 6, 2010

The concept of utilizing Contract Research Organizations (CROs) is not foreign to many large and small pharma and biotech organizations. However, in today's competitive markets, pharma and biotech organizations are looking beyond the costs savings and focusing on how they will be leveraging CROs to advance drug discovery and development. Organizations are now viewing CROs as a strategic asset and a key contributor to the drug development process.

Sterile Injectables Contract Manufacturing Market Outlook

February 28, 2008

Jubilant News for Hollister-Stier | www.contractpharma.com

As demand of the sterile injectables products grows, more and more contract manufacturers are evaluating this landscape as a potential opportunity for growth.  The major concerns in this market outlook are how complex is the technology, how much capacity is needed and will this technology be the future for the pharmaceutical and biotech companies and are contract manufacturers ready/capable of the challenges. 

Sustainable Cost Cutting Efforts Through Strategic Partnerships

January 25, 2008

Pfizer, Novartis, Amgen: cutting costs could boost short-term profits | www.pharmaceutical-business-review.com

In today's ever changing pharmaceutical/biotech landscape, manufacturers need to take an aggressive approach to reduce cost while developing their robust pipelines.  To do this successfully, manufacturers need to focus on their core competencies as strategically determined by the senior management of the organization.  Companies now need to focus on: 1.  Outsourcing of none strategic activities such as manufacturing/packaging, some development activities and clinical operations 2.  Look at strategic licensing partnerships to drive more enhanced pipelines 3.  Continue to look at the global landscape to leverage effective operational opportunities

Page : 11 to 3 of 3

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

Leading institutions connect with Hany Salama through GLG